BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 21784529)

  • 1. Short-term lower leg growth in 5- to 11-year-old asthmatic children using beclomethasone dipropionate inhalers with chlorofluorocarbon or hydrofluoroalkane propellants: a 9-week, open-label, randomized, crossover, noninferiority study.
    Wolthers OD; Walters EG
    Clin Ther; 2011 Aug; 33(8):1069-76. PubMed ID: 21784529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol.
    Fireman P; Prenner BM; Vincken W; Demedts M; Mol SJ; Cohen RM
    Ann Allergy Asthma Immunol; 2001 May; 86(5):557-65. PubMed ID: 11379808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term growth and adrenal function in children with asthma treated with inhaled beclomethasone dipropionate hydrofluoroalkane-134a.
    Wolthers OD
    Pediatr Allergy Immunol; 2006 Dec; 17(8):613-9. PubMed ID: 17121590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects.
    Chrousos GP; Ghaly L; Shedden A; Iezzoni DG; Harris AG
    Chest; 2005 Jul; 128(1):70-7. PubMed ID: 16002918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the Easibreathe inhaler for the treatment of paediatric asthma.
    Farmer IS; Middle M; Savic J; Perri VL; Herdman MJ
    Respir Med; 2000 Jan; 94(1):57-63. PubMed ID: 10714480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children.
    Pedersen S; Warner J; Wahn U; Staab D; Le Bourgeois M; Van Essen-Zandvliet E; Arora S; Szefler SJ;
    Pediatrics; 2002 Jun; 109(6):e92. PubMed ID: 12042586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: a 6-month, open- label, randomized trial.
    Szefler SJ; Warner J; Staab D; Wahn U; Le Bourgeois M; van Essen-Zandvliet EE; Arora S; Pedersen S;
    J Allergy Clin Immunol; 2002 Jul; 110(1):45-50. PubMed ID: 12110818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of HFA-134a beclomethasone dipropionate extra-fine aerosol over six months.
    Boulet LP; Cartier A; Ernst P; Larivée P; Laviolette M
    Can Respir J; 2004 Mar; 11(2):123-30. PubMed ID: 15045043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in moderate asthma: 400 microg hydrofluoroalkane beclomethasone dipropionate vs 800 microg chlorofluorocarbon beclomethasone dipropionate. The Study Group.
    Juniper EF; Buist AS
    Chest; 1999 Nov; 116(5):1297-303. PubMed ID: 10559091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC-beclomethasone dipropionate.
    Dahl R; Ringdal N; Ward SM; Stampone P; Donnell D
    Br J Clin Pract; 1997; 51(1):11-5. PubMed ID: 9158265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study.
    Barnes N; Price D; Colice G; Chisholm A; Dorinsky P; Hillyer EV; Burden A; Lee AJ; Martin RJ; Roche N; von Ziegenweidt J; Israel E
    Clin Exp Allergy; 2011 Nov; 41(11):1521-32. PubMed ID: 21752116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of HFA- and CFC-beclomethasone dipropionate on the bronchial response to methacholine (MCh) in mild asthma.
    Micheletto C; Guerriero M; Tognella S; Dal Negro RW
    Respir Med; 2005 Jul; 99(7):850-5. PubMed ID: 15939246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical studies in asthmatics with a new non-extra fine HFA formulation of beclometasone dipropionate (BDP Modulite).
    Bousquet J; Cantini L
    Respir Med; 2002 Aug; 96 Suppl D():S17-27. PubMed ID: 12201078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol.
    Thompson PJ; Davies RJ; Young WF; Grossman AB; Donnell D
    Respir Med; 1998 Jun; 92 Suppl A():33-9. PubMed ID: 9850361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study to assess lung deposition of HFA-beclomethasone and CFC-beclomethasone from a pressurized metered dose inhaler with and without add-on spacers and using varying breathhold times.
    Leach CL; Colice GL
    J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23(6):355-61. PubMed ID: 20575669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influence of changing from chlorofluorocarbon (CFC)-beclomethasone dipropionate (BDP) to hydrofluoroalkane (HFA)-BDP on pulmonary function in asthmatic children].
    Yoshida Y; Inoue T; Nishikido T; Kameda M; Takamatu I; Doi S
    Arerugi; 2007 Dec; 56(12):1502-9. PubMed ID: 18195554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose.
    Davies RJ; Stampone P; O'Connor BJ
    Respir Med; 1998 Jun; 92 Suppl A():23-31. PubMed ID: 9850360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on lung function, symptoms, and bronchial hyperreactivity of low-dose inhaled beclomethasone dipropionate given with HFA-134a or CFC propellant.
    Woodcock A; Williams A; Batty L; Masterson C; Rossetti A; Cantini L
    J Aerosol Med; 2002; 15(4):407-14. PubMed ID: 12581507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma.
    Gross G; Thompson PJ; Chervinsky P; Vanden Burgt J
    Chest; 1999 Feb; 115(2):343-51. PubMed ID: 10027430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-Term Growth During Treatment with Inhaled Fluticasone Propionate/Formoterol, Fluticasone and Beclomethasone Treatment.
    Wolthers OD; Moore A; Mersmann S; Dissanayake S
    J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):373-380. PubMed ID: 28510491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.